CLINICAL USE

Treatment of moderate to severe rheumatoid arthritis in people who have not responded adequately to other treatment

DOSE IN NORMAL RENAL FUNCTION

<60 kg: 500 mg, 60–100 kg: 750 mg, >100 kg: 1000 mgevery 4 weeks after loading

PHARMACOKINETICS

  • Molecular weight                           :92 000
  • %Protein binding                           :No data
  • %Excreted unchanged in urine     : No data
  • Volume of distribution (L/kg)       :0.07
  • half-life – normal/ESRD (hrs)      :13.1 days/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function. Use with caution
  • <10           : Dose as in normal renal function. Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                        : Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HD                             :Unlikely to be dialysed. Dose as in GFR<<10 mL/min
  • HDF/high flux           :Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • CAV/VVHD               :Unlikely to be dialysed. Dose as in GFR10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsVaccines: avoid concomitant use with live vaccines

    ADMINISTRATION

    Reconstition

    With 10 mL of water for injection per vial

    Route

    IV infusion

    Rate of Administration

    Over 30 minutes

    Comments

    DO NOT SHAKE when reconstituting Add dose to 100 mL of sodium chloride 0.9%

    OTHER INFORMATION

    Stable for 24 hours at 2–8°C if made under aseptic conditionsAdminister with an infusion set with a low protein binding filter (pore size 0.2–1.2 μm)Manufacturer does not have any information on its use in renal impairment. Main side effects are infections and malignancies, to which renal patients may be at increased risk, therefore use with caution

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia